A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
about
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapyRole of vaccine therapy for renal cell carcinoma in the era of targeted therapyImmunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patientsQuantification of HLA class I molecules on renal cell carcinoma using Edman degradationInduction of HLA-A*33-restricted cytotoxic lymphocytes against renal cell carcinoma targeting galectin 9 and PINCH.Therapeutic cancer vaccines: are we there yet?Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides.Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.Role of hypoxia-inducible factor-1α, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancerExpression of hypoxia-inducible protein 2 in renal cell carcinoma: A promising candidate for molecular targeting therapyPotential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancerVaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findingsRecent advances in the therapy of renal cancer.Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer.Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma.Active and passive immunotherapy: vaccines and antibodies.Update on vaccine development for renal cell cancer.A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.Carbonic anhydrase IX: historical and future perspectives.The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder.Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.Prognostic biomarkers of renal cell carcinoma: Recent advances.Prognostic markers and targeted therapies for renal cell carcinoma.Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinomaVaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease.Decitabine: a promising epi-immunotherapeutic agent in solid tumors.Next revolution in molecular theranostics: personalized medicine for urologic cancers.Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1.Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma.Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.Present status and future perspective of peptide-based vaccine therapy for urological cancer.Present and future perspectives on immunotherapy for advanced renal cell carcinoma: Going to the core or beating around the bush?Immunotherapy for renal cell carcinoma
P2860
Q26991589-41201A57-8224-4676-8BCF-4886B3F88EA1Q27016032-D9167784-C35B-496B-B1D6-F756C1FF196DQ28301672-71C39911-3027-461F-88AF-0F04FC9C1A36Q30313444-F1EEE798-24D1-43F1-9C81-EDF2A2FCB13EQ33798689-6BBF7EF8-22A3-4F94-9D06-2B82C1E0C853Q34265625-94CC9B57-765F-480D-97B4-7D86E8D0A049Q34786691-12F08950-76E6-40C2-BFC3-9F3E37B0FF32Q35181245-D3F97023-F6B0-4FBE-9B79-5AB0E9A0C49AQ35446852-22113724-A92D-4EAD-BE2A-594C8E1964C4Q36085682-F7CCADD8-AA8F-4851-B820-C550D8E9823CQ36216688-F1870A0C-B128-454C-9605-E60EC5DD001AQ36429759-49C468FB-7281-4866-8608-F1F49D7E5359Q36615603-BA6BA44B-FB8B-4A03-A370-05336D351247Q36717355-8BBBFB25-BED6-4083-9F13-5426D3060F0BQ36736462-082661FE-0397-43A6-BAD9-CA23557652B4Q36747387-CC70EB31-82E3-4FAC-9FA5-6F3F0EC36A5BQ36794818-2CD61341-2B4F-40F8-A44B-802EAB322CD4Q36989720-E654E432-76D3-43F2-BD59-0DF064C78E98Q37118188-6C6731DD-F032-4605-9B05-0442933AA5ACQ37145154-7DEB21C0-14D2-42E0-A78D-7AA98762AF7FQ37145181-5CF8ABEF-686E-48DF-B33B-0335644B9101Q37178648-3B26A6CE-A3CD-4047-BA5E-A01DA0AF6BBBQ37197505-7BDC1961-4114-48A1-BF3A-FF77003F957BQ37414359-92434008-9371-4FD1-81DC-4C4B1C9F3490Q37575248-1E5298B3-A2C7-46F1-B091-256DB19B9BACQ37892594-8868961B-9585-4C72-8193-9CCCC6424B2FQ38314204-B89479AA-451A-4D4B-8A57-8B75F11C4739Q38559336-DB25DFF4-8170-47C0-AB7C-EB6CAD8DC73FQ39162824-AD822873-6BDC-4180-B8CB-B5EC0C7E373FQ39396204-8B246E22-1E4F-4EAD-9DFD-C78A56208C54Q39985993-B27DB3C5-E3DF-4D60-8C70-A50C8FA08FD9Q46234210-97BDB17C-9EE6-4D68-AFFD-131593371F23Q47725715-7651CF70-BAA0-44FC-9621-E735D58F1854Q51158841-79EB731F-CF88-467E-A239-CE20EA0D228DQ58652034-1E4E1EFF-B589-4DD2-9660-CF2EADDA05EB
P2860
A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A phase I trial of vaccination ...... tastatic renal cell carcinoma.
@ast
A phase I trial of vaccination ...... tastatic renal cell carcinoma.
@en
A phase I trial of vaccination ...... tastatic renal cell carcinoma.
@nl
type
label
A phase I trial of vaccination ...... tastatic renal cell carcinoma.
@ast
A phase I trial of vaccination ...... tastatic renal cell carcinoma.
@en
A phase I trial of vaccination ...... tastatic renal cell carcinoma.
@nl
prefLabel
A phase I trial of vaccination ...... tastatic renal cell carcinoma.
@ast
A phase I trial of vaccination ...... tastatic renal cell carcinoma.
@en
A phase I trial of vaccination ...... tastatic renal cell carcinoma.
@nl
P2093
P1476
A phase I trial of vaccination ...... tastatic renal cell carcinoma.
@en
P2093
Hirotsugu Uemura
Kazuhiro Yoshikawa
Kiyohide Fujimoto
Kyogo Itoh
Motoyoshi Tanaka
Motoyoshi Yoshikawa
Shigeya Uejima
Yoshihiko Hirao
P304
P356
10.1158/1078-0432.CCR-05-2253
P407
P577
2006-03-01T00:00:00Z